Press release Stine Krag Brunvold 3/21/24 Press release Stine Krag Brunvold 3/21/24 NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine Read More Other news Stine Krag Brunvold 3/8/24 Other news Stine Krag Brunvold 3/8/24 International Women’s Day 2024 – “My wish for Women: Dare and just go for it” – Sabine Dandiguian, Managing Partner, Jeito, shares her inspiring journey Read More Other news Stine Krag Brunvold 3/8/24 Other news Stine Krag Brunvold 3/8/24 International Women’s Day 2024 – Celebrating all the incredible women at NMD Pharma Read More Press release Stine Krag Brunvold 3/1/24 Press release Stine Krag Brunvold 3/1/24 NMD Pharma announces poster and oral presentations on skeletal muscle targeted ClC-1 therapy at two leading neuromuscular disease conferences Read More Press release Stine Krag Brunvold 1/22/24 Press release Stine Krag Brunvold 1/22/24 NMD Pharma Appoints Morten Bull as SVP, General Counsel and Head of People & Business Services Read More Press release Stine Krag Brunvold 11/15/23 Press release Stine Krag Brunvold 11/15/23 NMD Pharma Raises €75 Million (~$80 million) in a Series B Financing Read More Press release Stine Krag Brunvold 10/3/23 Press release Stine Krag Brunvold 10/3/23 NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society Read More Press release Stine Krag Brunvold 9/26/23 Press release Stine Krag Brunvold 9/26/23 NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy Read More Press release Stine Krag Brunvold 9/8/23 Press release Stine Krag Brunvold 9/8/23 NMD Pharma to host a Satellite Symposium and present new clinical data at the 148th Annual Meeting of the American Neurological Association Read More Insights Stine Krag Brunvold 8/15/23 Insights Stine Krag Brunvold 8/15/23 Spinal Muscular Atrophy (SMA) Patient Perspective: Our Clinical Trial Manager Thomas Grønnebæk caught up with Claus Read More Other news Stine Krag Brunvold 6/28/23 Other news Stine Krag Brunvold 6/28/23 We will be in Orlando, Florida from 28-30 June for the Annual SMA Research and Clinical Care Conference Read More Press release Stine Krag Brunvold 6/20/23 Press release Stine Krag Brunvold 6/20/23 NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2 Read More Press release Stine Krag Brunvold 6/9/23 Press release Stine Krag Brunvold 6/9/23 NMD Pharma to Present Results from the Charcot-Marie-Tooth ESTABLISH Study at the Peripheral Nerve Society Annual Meeting Read More Press release Stine Krag Brunvold 6/1/23 Press release Stine Krag Brunvold 6/1/23 NMD Pharma appoints Daniel Brennan as SVP, Corporate and Commercial Strategy Read More Press release Stine Krag Brunvold 5/23/23 Press release Stine Krag Brunvold 5/23/23 NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics study of NMD1343 Read More Other news Stine Krag Brunvold 5/9/23 Other news Stine Krag Brunvold 5/9/23 NMD Pharma to Attend Bio€quity Europe 2023 Read More Other news Stine Krag Brunvold 3/7/23 Other news Stine Krag Brunvold 3/7/23 We will be in Basel for BIO-Europe Spring Read More Events Stine Krag Brunvold 2/28/23 Events Stine Krag Brunvold 2/28/23 Rare Disease Day, 28 February 2023 Read More Other news Stine Krag Brunvold 1/4/23 Other news Stine Krag Brunvold 1/4/23 Meet us at J.P. Morgan Healthcare Conference on January 9-12, 2023 in San Francisco Read More Press release Stine Krag Brunvold 1/3/23 Press release Stine Krag Brunvold 1/3/23 Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors Read More Newer Posts Older Posts
Press release Stine Krag Brunvold 3/21/24 Press release Stine Krag Brunvold 3/21/24 NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine Read More
Other news Stine Krag Brunvold 3/8/24 Other news Stine Krag Brunvold 3/8/24 International Women’s Day 2024 – “My wish for Women: Dare and just go for it” – Sabine Dandiguian, Managing Partner, Jeito, shares her inspiring journey Read More
Other news Stine Krag Brunvold 3/8/24 Other news Stine Krag Brunvold 3/8/24 International Women’s Day 2024 – Celebrating all the incredible women at NMD Pharma Read More
Press release Stine Krag Brunvold 3/1/24 Press release Stine Krag Brunvold 3/1/24 NMD Pharma announces poster and oral presentations on skeletal muscle targeted ClC-1 therapy at two leading neuromuscular disease conferences Read More
Press release Stine Krag Brunvold 1/22/24 Press release Stine Krag Brunvold 1/22/24 NMD Pharma Appoints Morten Bull as SVP, General Counsel and Head of People & Business Services Read More
Press release Stine Krag Brunvold 11/15/23 Press release Stine Krag Brunvold 11/15/23 NMD Pharma Raises €75 Million (~$80 million) in a Series B Financing Read More
Press release Stine Krag Brunvold 10/3/23 Press release Stine Krag Brunvold 10/3/23 NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society Read More
Press release Stine Krag Brunvold 9/26/23 Press release Stine Krag Brunvold 9/26/23 NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy Read More
Press release Stine Krag Brunvold 9/8/23 Press release Stine Krag Brunvold 9/8/23 NMD Pharma to host a Satellite Symposium and present new clinical data at the 148th Annual Meeting of the American Neurological Association Read More
Insights Stine Krag Brunvold 8/15/23 Insights Stine Krag Brunvold 8/15/23 Spinal Muscular Atrophy (SMA) Patient Perspective: Our Clinical Trial Manager Thomas Grønnebæk caught up with Claus Read More
Other news Stine Krag Brunvold 6/28/23 Other news Stine Krag Brunvold 6/28/23 We will be in Orlando, Florida from 28-30 June for the Annual SMA Research and Clinical Care Conference Read More
Press release Stine Krag Brunvold 6/20/23 Press release Stine Krag Brunvold 6/20/23 NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2 Read More
Press release Stine Krag Brunvold 6/9/23 Press release Stine Krag Brunvold 6/9/23 NMD Pharma to Present Results from the Charcot-Marie-Tooth ESTABLISH Study at the Peripheral Nerve Society Annual Meeting Read More
Press release Stine Krag Brunvold 6/1/23 Press release Stine Krag Brunvold 6/1/23 NMD Pharma appoints Daniel Brennan as SVP, Corporate and Commercial Strategy Read More
Press release Stine Krag Brunvold 5/23/23 Press release Stine Krag Brunvold 5/23/23 NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics study of NMD1343 Read More
Other news Stine Krag Brunvold 5/9/23 Other news Stine Krag Brunvold 5/9/23 NMD Pharma to Attend Bio€quity Europe 2023 Read More
Other news Stine Krag Brunvold 3/7/23 Other news Stine Krag Brunvold 3/7/23 We will be in Basel for BIO-Europe Spring Read More
Events Stine Krag Brunvold 2/28/23 Events Stine Krag Brunvold 2/28/23 Rare Disease Day, 28 February 2023 Read More
Other news Stine Krag Brunvold 1/4/23 Other news Stine Krag Brunvold 1/4/23 Meet us at J.P. Morgan Healthcare Conference on January 9-12, 2023 in San Francisco Read More
Press release Stine Krag Brunvold 1/3/23 Press release Stine Krag Brunvold 1/3/23 Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors Read More
